Health and Fitness Health and Fitness
Tue, September 13, 2011
Mon, September 12, 2011

Teva Presentations at Bank Conference


Published on 2011-09-12 06:32:16 - Market Wire
  Print publication without navigation


JERUSALEM--([ BUSINESS WIRE ])--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the Bank of America Merrill Lynch Global Healthcare Conference in London and at the Morgan Stanley Global Healthcare Conference in New York. Both presentations will take place on Wednesday, September 14, 2011.

What: Teva Presentation at the Bank of America Merrill Lynch Global Healthcare Conference

Who: Dr. Gerard van Odijk, President & CEO, Teva Europe

When: Wednesday, September 14, 2011, at 10:45 AM BT

Where:[ http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-irhome ] or

[ http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=TEVA&item_id=4195785 ]

What: Teva Presentation at the Morgan Stanley Global Healthcare Conference

Who: William Marth, President & CEO, Teva Pharmaceuticals - Americas

When: Wednesday, September 14, 2011, at 2:10 PM EDT

Where:[ http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-irhome ] or

[ http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=TEVA&item_id=4158969 ]

How: Live over the Internet a" log on to the Web at the address above and register for the event (approx. 10 minutes before). An archive of the webcast will be available on Teva's website.

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 40,000 people around the world and reached $16.1 billion in net sales in 2010.

Contributing Sources